Close Menu

NEW YORK – Myriad Genetics said on Tuesday after the close of the market that its revenues for the three months ended Dec. 31, 2020 declined 21 percent year over year.

Total revenues for the period were $154.6 million, down from $195.1 million. It beat the consensus Wall Street estimate of $150.4 million.

The Salt Lake City-based firm is in the process of changing its financial year to match the calendar year. It previously ended its fiscal year on June 30, but even with the change to match the calendar year, the company didn't report full-year financial results.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.